NR1H4 and chronic kidney disease: Given that the nuclear receptor FXR is known to be expressed in the kidney and can modulate inflammation, it is possible that the BA dysmetabolism described by Summers et al. could promote CKD progression by losing the anti-inflammatory action of UDCA when it acts as an FXR ligand within the kidney (Table 1).